An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Study sponsor: Delcath Systems Inc. · DCTH
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-03-01Estimated
Enrollment · participants30Estimated
Source updated2023-12-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.